STUDIES OF THYROID DISEASES

罗宾斯博士参加了NCI/DOE项目，研究甲状腺 切尔诺贝利核反应堆事故的影响。 的 白俄罗斯的病例对照研究已经完成，正在提交 出版。 结果清楚地表明，甲状腺癌病例 甲状腺辐射剂量高于年龄、性别 和诊断途径。 优势比大约是6。 规划 在白俄罗斯开展前瞻性队列研究， 乌克兰将确定甲状腺癌发展的风险系数 在放射性碘暴露完成后，这些研究 现在被激活。 罗宾斯博士参与了国家卫生研究院的组成部分 重组人促甲状腺激素的机构间III期评价 （rhTSH）用于管理接受甲状腺治疗的患者 癌 提交出版的初步调查结果表明， rhTSH可有效促进肿瘤残留物的放射性碘摄取 或转移，而患者甲状腺激素保持正常 更换. 进一步的研究调查了不同的 剂量方案对rhTSH诱导肿瘤摄取能力的影响 以诱导血清甲状腺球蛋白浓度升高，如 食品药品监督管理局在批准前要求 临床使用的药物，正在组装提交。

Dr. Robbins participates in the NCI/DOE project to study the thyroid effects of the nuclear power reactor accident in Chernobyl. The case-control study in Belarus has been completed and is being submitted for publication. The results clearly indicate that thyroid cancer cases have a higher thyroid radiation dose than controls matched for age, sex and route to diagnosis. The odds ratio is approximately six. Planning for the establishment of prospective cohort studies in Belarus and Ukraine to determine the risk coefficient for thyroid cancer development after exposure to radioiodines has been completed and these studies are now being activated. Dr. Robbins participates with the NIH component of the interinstitutional Phase III evaluation of recombinant human TSH (rhTSH) for use in the management of patients treated for thyroid cancer. Initial findings, submitted for publication, indicate that rhTSH is effective in stimulating radioiodine uptake in tumor remnants or metastases while the patient remains euthyroid on thyroid hormone replacement. Further studies investigating the effects of different dose schedules on the ability of rhTSH to induce tumor uptake as well as to induce an increase in serum thyroglobulin concentration, as required by the Food and Drug Administration prior to approval of the drug for clinical use, are being assembled for submission.